Screening of Therapeutic Strategies for Huntington's Disease in YAC128 Transgenic Mice

被引:18
|
作者
Gil-Mohapel, Joana M. [1 ]
机构
[1] Univ Victoria, Div Med Sci, Isl Med Program, Victoria, BC V8W 2Y2, Canada
基金
加拿大自然科学与工程研究理事会;
关键词
Apoptosis; Behavioral deficits; Excitotoxicity; Huntington's disease; Neuropathology; Therapy; YAC128 transgenic mice; TRANSGLUTAMINASE INHIBITOR CYSTAMINE; NEURONAL INTRANUCLEAR INCLUSIONS; RANDOMIZED CONTROLLED-TRIAL; FULL-LENGTH HUNTINGTIN; MOUSE MODEL; MUTANT HUNTINGTIN; TISSUE TRANSGLUTAMINASE; WILD-TYPE; CASPASE CLEAVAGE; STRIATAL NEURODEGENERATION;
D O I
10.1111/j.1755-5949.2011.00246.x
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Huntington's disease (HD) is a hereditary neurodegenerative disorder caused by an unstable expansion of cytosine-adenine-guanine (CAG) repeats in the HD gene. The symptoms include cognitive dysfunction and severe motor impairment with loss of voluntary movement coordination that is later replaced by bradykinesia and rigidity. The neuropathology is characterized by neuronal loss mainly in the striatum and cortex, and the appearance of neuronal intranuclear inclusions of mutant huntingtin. The mechanisms responsible for neurodegeneration are still not fully understood although excitotoxicity and a consequent increase in intracellular calcium concentration as well as the activation of caspases and calapins are known to play a key role. There is currently no satisfactory treatment or cure for this disease. The YAC128 transgenic mice express the full-length human HD gene with 128 CAG repeats and constitute a unique model for the study of HD as they replicate the slow and biphasic progression of behavioral deficits characteristic of the human condition and show striatal neuronal loss. As such, these transgenic mice have been an invaluable model not only for the elucidation of the neurodegenerative pathways in HD, but also for the screening and development of new therapeutic approaches. Here, I will review the unique characteristics of this transgenic HD model and will provide a summary of the therapies that have been tested in these mice, namely: potentiation of the protective roles of wild-type huntingtin and mutant huntingtin aggregation, transglutaminase inhibition, inhibition of glutamate- and dopamine-induced toxicity, apoptosis inhibition, use of essential fatty acids, and the novel approach of intrabody gene therapy. The insights obtained from these and future studies will help identify potential candidates for clinical trials and will ultimately contribute to the discovery of a successful treatment for this devastating neurodegenerative disorder.
引用
收藏
页码:77 / 86
页数:10
相关论文
共 50 条
  • [1] EVALUATION OF HIPPOCAMPAL NEUROGENESIS IN YAC128 HUNTINGTON'S DISEASE TRANSGENIC MICE
    Gil-Mohapel, J.
    Simpson, J. M.
    Pouladi, M. A.
    Hayden, M.
    Christie, B. R.
    [J]. EUROPEAN PSYCHIATRY, 2009, 24
  • [2] Neuroinflammation in the YAC128 transgenic mouse model of Huntington's disease
    Connolly, C.
    Thiele, J.
    Beck, J.
    Lefroy, C.
    Hill, A.
    Leavitt, B. R.
    [J]. MOVEMENT DISORDERS, 2012, 27 : S58 - S58
  • [3] EVALUATION OF PRIDOPIDINE IN THE TRANSGENIC YAC128 MOUSE MODEL OF HUNTINGTON'S DISEASE
    Miralles, Marta Garcia
    Tan, Liang Juin
    Lim, Madeline
    Geva, Michal
    Hayden, Michael R.
    Pouladi, Mahmoud A.
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2016, 87 : A92 - A92
  • [4] Antidepressant Effects of Probucol on Early-Symptomatic YAC128 Transgenic Mice for Huntington's Disease
    Nascimento-Castro, Cristine de Paula
    Wink, Ana Claudia
    da Fonseca, Victor Silva
    Bianco, Claudia Daniele
    Winkelmann-Duarte, Elisa C.
    Farina, Marcelo
    Rodrigues, Ana Lucia S.
    Gil-Mohapel, Joana
    de Bem, Andreza Fabro
    Brocardo, Patricia S.
    [J]. NEURAL PLASTICITY, 2018, 2018
  • [5] THERAPEUTIC EFFECT OF ANTISENSE OLIGONUCLEOTIDE TREATMENT IN YAC128 HUNTINGTON MICE
    Kuijper, Elsa
    Overzier, Maurice
    Suidgeest, Ernst
    Van der Weerd, Louise
    Toonen, Lodewijk
    Van Roon-Mom, Willeke
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2022, 93 : A85 - A85
  • [6] Evaluation of pridopidine in the transgenic YAC128 mouse model of Huntington disease
    Garcia-Miralles, M.
    Yosuf, N. A. B. M.
    Tan, J. Y.
    Kusko, R.
    Tan, L. J.
    Xu, X.
    Orbach, A.
    Geva, M.
    Hayden, M. R.
    Pouladi, M. A.
    [J]. JOURNAL OF NEUROCHEMISTRY, 2017, 142 : 219 - 219
  • [7] Glutamate receptor abnormalities in the YAC128 transgenic mouse model of Huntington's disease
    Benn, C. L.
    Slow, E. J.
    Farrell, L. A.
    Graham, R.
    Deng, Y.
    Hayden, M. R.
    Cha, J.-H. J.
    [J]. NEUROSCIENCE, 2007, 147 (02) : 354 - 372
  • [8] Light and electron microscopic characterization of the evolution of cellular pathology in YAC128 Huntington's disease transgenic mice
    Bayram-Weston, Zubeyde
    Jones, Lesley
    Dunnett, Stephen B.
    Brooks, Simon P.
    [J]. BRAIN RESEARCH BULLETIN, 2012, 88 (2-3) : 137 - 147
  • [9] BDNF Overexpression in the Forebrain Rescues Huntington's Disease Phenotypes in YAC128 Mice
    Xie, Yuxiang
    Hayden, Michael R.
    Xu, Baoji
    [J]. JOURNAL OF NEUROSCIENCE, 2010, 30 (44): : 14708 - 14718
  • [10] Time-Course Analysis of Protein and Lipid Oxidation in the Brains of Yac128 Huntington's Disease Transgenic Mice
    Brocardo, Patricia S.
    McGinnis, Eric
    Christie, Brian R.
    Gil-Mohapel, Joana
    [J]. REJUVENATION RESEARCH, 2016, 19 (02) : 140 - 148